(TXG) 10X Genomics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88025U1097
TXG: Instruments, Consumables, Software, Assays, Analyzers
10X Genomics Inc. (NASDAQ:TXG) is a leading life science technology company specializing in the development and commercialization of innovative instruments, consumables, and software for biological system analysis. The company operates globally, serving customers across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. Its product portfolio includes the Chromium platform, which enables single-cell and multiomic analysis through microfluidic chips, consumables, and instruments like the Chromium X Series. The Visium platform offers spatial gene expression and protein analysis solutions, including the Visium CytAssist instrument, which streamlines workflows for spatial biology applications. Additionally, the Xenium Analyzer allows researchers to detect RNA targets in fresh frozen or FFPE tissue sections while preserving cellular spatial information. The company serves a diverse range of customers, including academic institutions, government laboratories, and biopharmaceutical and biotechnology firms. Originally named 10X Technologies, Inc., the company rebranded as 10X Genomics Inc. in November 2014 and was incorporated in 2012. It is headquartered in Pleasanton, California.
From a technical perspective, TXG stock has shown declining momentum, with its SMA 20, 50, and 200 all below the last price of $8.43. This indicates bearish sentiment in the short to long term. The ATR of 0.63 reflects moderate volatility. Fundamentally, the company has a market cap of $997.39M, with a forward P/E of 196.08, suggesting high valuations relative to expected earnings. The P/B ratio of 1.47 indicates that the stock is trading at a premium to its book value. However, the negative RoE of -25.72% highlights ongoing profitability challenges.
Additional Sources for TXG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TXG Stock Overview
Market Cap in USD | 997m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2019-09-12 |
TXG Stock Ratings
Growth Rating | -90.3 |
Fundamental | -20.4 |
Dividend Rating | 0.0 |
Rel. Strength | -64.5 |
Analysts | 3.76/5 |
Fair Price Momentum | 4.81 USD |
Fair Price DCF | - |
TXG Dividends
No Dividends PaidTXG Growth Ratios
Growth Correlation 3m | -87.8% |
Growth Correlation 12m | -90.3% |
Growth Correlation 5y | -86.1% |
CAGR 5y | -36.25% |
CAGR/Max DD 5y | -0.38 |
Sharpe Ratio 12m | -1.41 |
Alpha | -76.57 |
Beta | 0.993 |
Volatility | 78.91% |
Current Volume | 4978.5k |
Average Volume 20d | 3362.6k |
As of May 09, 2025, the stock is trading at USD 8.63 with a total of 4,978,545 shares traded.
Over the past week, the price has changed by +6.54%, over one month by +20.87%, over three months by -28.44% and over the past year by -65.97%.
Neither. Based on ValueRay Fundamental Analyses, 10X Genomics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.43 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TXG as of May 2025 is 4.81. This means that TXG is currently overvalued and has a potential downside of -44.26%.
10X Genomics has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold TXG.
- Strong Buy: 6
- Buy: 2
- Hold: 8
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, TXG 10X Genomics will be worth about 5.5 in May 2026. The stock is currently trading at 8.63. This means that the stock has a potential downside of -36.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 15.3 | 76.9% |
Analysts Target Price | 20.1 | 133.4% |
ValueRay Target Price | 5.5 | -36.8% |